Table 2.

Comparative Benefit-to-harm and Cost-to-effectiveness of 11 Selected Items^* among Three Programs: National Lung Screening Trial (NLST), U.S. Preventive Services Task Force (USPSTF), and the Our Study^**

Setting of LDCT annual screening entry criteria and comparisons	1. Total CT Examinations, Including Screening, setting NLST at 100% as reference	2. Screening Detected Cases, setting NLST at 100% as reference	3. Reduction in Lung Cancer mortality in %	4. Total Cases Detected at an Early Stage, %	5. Average Screening Examinations per Person Screened, N	6. Screening Examinations per Lung Cancer Death Averted, N	7. Screening Examinations per Life-Year Gained, N	8. Average False-Positive Results per Person Screened, N	9. Over-diagnosis % of all cases	10. Over-diagnosis % of screening-detected cases	11.Radiation-Related Lung Cancer Deaths, N
NLST	100	100	12.3	48.4	13.8	577	49	3.2	2.7	8.7	24
USPSTF vs. NLST	+ 8.2	+19.7	+1.7	+2.1	+1.1	+3	+3	+0.4	+1.0	+1.2	+0
Our study* vs. NLST	+29.0	+39.0	+3.5	+3.7	+3.1	+6	+5	+0.7	+1.6	+1.3	+1
Our study* vs. USPSTF	+19.3	+16.1	+1.8	+1.6	+2.0	+3	+2	+0.5	+0.6	+0.1	+1

^*Derived and adapted from Tables 1-2 of de Koning et al, Annals of Internal Medicine, 2014.

^**Used a screening program most similar to A-55-80-30-25 in de Koning et al, Annals of Internal Medicine, 2014 (i.e., A-55-80-30-30):

Annual-Start Age (year)-Stop Age (year)-Pack-Years Smoked-Years since Quitting, which is also supported by our previous work (references 6 & 7).